ClinicalTrials.gg
RecruitingNCT07558304SMART-BUpdated Oct 1, 2026

Suprapapillary Metal Stent vs. Routine Transpapillary Drainage in Malignant Hilar Biliary Obstruction (SMART-B Trial)

An interventional study of Percutaneous transpapillary internal-external biliary drainage and Percutaneous suprapapillary biliary drainage with self-expanding metal stent in Cholangiocarcinoma, Bile Duct Neoplasms and Malignant Biliary Obstruction, sponsored by Hospital de Clinicas de Porto Alegre. Recruiting at 2 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Hospital de Clinicas de Porto Alegre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 1, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Cholangiocarcinoma with a site in Brazil — 3 open to participants now, 6 under way, 2 of them phase 3. Cholangiocarcinoma · Brazil.

Planned enrollment
7th of 10
84 · median 190
Started
2026
the only one that year
No phase
Only one
of the 11
Registered
11th of 11
by date
Lead sponsor
1 of 11
Hospital de Clinicas de Porto Alegre

Among the 11 studies in Cholangiocarcinoma with a site in Brazil, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is the only one with no phase, and was the 11th registered.

Cholangiocarcinoma

826 studies on the registry are indexed under Cholangiocarcinoma; 289 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

3 of the 11 studies in Cholangiocarcinoma with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Cholangiocarcinoma with a site in Brazil, or all of them as a file.
02

Study summary

Malignant hilar biliary obstruction is a condition in which the bile ducts near the liver become blocked due to cancer. This blockage can lead to jaundice (yellowing of the skin and eyes), itching, infection, and impaired liver function. To relieve the obstruction, doctors commonly perform procedures to drain bile and restore its flow.

There are different techniques available for biliary drainage. One common method is percutaneous transpapillary internal-external drainage, in which a catheter is placed through the liver and across the natural opening of the bile duct into the intestine. Another approach is percutaneous suprapapillary drainage using a self-expanding metal stent, which allows bile to drain without crossing into the intestine and may reduce the risk of contamination and infection.

Currently, there is no clear consensus on which of these two techniques is safer or more effective for patients with malignant proximal biliary obstruction. Some studies suggest that avoiding manipulation of the intestinal opening of the bile duct may reduce complications such as infection, but high-quality comparative evidence is lacking.

The purpose of this study is to compare percutaneous suprapapillary drainage with a self-expanding metal stent versus routine percutaneous transpapillary internal-external drainage in patients with malignant proximal biliary obstruction. The study aims to compare the rate of drainage-related complications between the two techniques, as well as to evaluate treatment success, stent patency, and the need for reintervention. In addition, in patients with potentially resectable disease undergoing preoperative biliary drainage, the study will assess and compare surgical outcomes between the two approaches. The results of this study may help determine the safest and most effective drainage strategy for these patients and improve future clinical decision-making.

Read the detailed description

Malignant hilar biliary obstruction is most commonly associated with perihilar cholangiocarcinoma and represents a complex clinical condition characterized by impaired bile flow at or above the hepatic duct confluence. The resulting cholestasis may lead to progressive hepatic dysfunction, increased risk of infectious complications, and reduced tolerance to systemic or surgical therapies. In selected patients, preoperative biliary drainage is performed to optimize liver function and reduce perioperative risk prior to major hepatectomy.

Percutaneous biliary drainage is widely used in this setting due to its ability to selectively decompress specific hepatic segments, particularly in complex hilar strictures. The conventional approach consists of transpapillary internal-external drainage, in which a catheter is advanced across the obstruction and through the papilla into the duodenum. While effective in achieving biliary decompression, this technique may disrupt the function of the sphincter of Oddi and facilitate duodenobiliary reflux, which has been implicated as a potential mechanism for infectious complications.

Percutaneous suprapapillary drainage with placement of a self-expanding metal stent represents an alternative strategy. By avoiding transpapillary manipulation, this approach preserves sphincter function and may reduce bacterial contamination of the biliary tree. Early clinical data suggest a favorable safety profile, particularly regarding infectious outcomes; however, direct comparisons with conventional transpapillary drainage remain limited, and available studies are constrained by methodological limitations.

An additional area of uncertainty relates to patients with potentially resectable disease. In this subgroup, the choice of drainage technique may influence not only peri-procedural outcomes but also subsequent surgical management. Concerns have been raised regarding the potential impact of metallic stents on operative complexity and resectability, although robust data are lacking.

This randomized clinical trial is designed to compare two percutaneous drainage strategies within a standardized institutional framework. Patients with an indication for percutaneous biliary drainage will be allocated to receive either transpapillary internal-external drainage or suprapapillary drainage with a self-expanding metal stent. The study includes both patients with unresectable disease and those with potentially resectable malignancies, allowing for evaluation across different clinical scenarios.

All procedures will be performed by experienced interventional radiologists using uniform technical protocols, and patients will be managed according to institutional standards of care. Follow-up will include clinical, laboratory, and imaging assessment as appropriate to routine practice.

The study is designed to generate comparative evidence regarding the safety and performance of these two techniques. In addition, a prespecified subgroup analysis will focus on patients with potentially resectable cholangiocarcinoma undergoing preoperative biliary drainage, in order to explore the impact of drainage strategy on subsequent surgical outcomes.

03

Conditions studied

  • Cholangiocarcinoma
  • Bile Duct Neoplasms
  • Malignant Biliary Obstruction

Keywords

  • Cholangiocarcinoma
  • Percutaneous biliary drainage
  • Self-expanding metal stent
  • Suprapapillary drainage
  • Malignant hilar biliary obstruction
  • Malignant Biliary Obstruction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years.
  2. Malignant proximal biliary obstruction on imaging (magnetic resonance cholangiopancreatography or contrast-enhanced abdominal computed tomography) with histopathological confirmation or high clinical and radiological suspicion.
  3. Total > 3 mg/dL.
  4. Patients not candidates for potentially curative surgical resection due to locally advanced disease, disease, or inadequate clinical condition.
  5. Patients with potentially resectable neoplasms, defined as the possibility of achieving complete resection (R0), who meet at least one of the following criteria:

5.1 Estimated future liver remnant \<40%, in whom percutaneous portal vein embolization of the side to be resected will also be indicated after initial drainage.

5.2 Prolonged jaundice with total bilirubin >10 mg/dL for more than 14 days. 5.3 Malnutrition, defined as ≥10% unintentional weight loss or albumin \<3 g/dL, presumably attributable to cholestasis.

5.4 Indication for chemotherapy.

Exclusion criteria

Exclusion Criteria:

  1. Tumor with distal extension to the duodenal papilla, precluding suprapapillary drainage.
  2. Prior biliary drainage procedure, either percutaneous (PTBD) or endoscopic (ERCP).
  3. Acute cholangitis, clinically defined as fever (axillary temperature >38°C) and leukocytosis (white blood cell count >10,000/mm³).
  4. Uncorrectable coagulopathy.
  5. Iodinated contrast allergy not amenable to desensitization.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Active comparator
    Transpapillary internal-external drainage

    Participants undergo percutaneous transpapillary internal-external biliary drainage with placement of a catheter across the obstruction and through the papilla into the duodenum, according to standard institutional practice.

    Procedure: Percutaneous transpapillary internal-external biliary drainage

  • Active comparator
    Suprapapillary Self-Expanding Metal Stent Drainage

    Participants undergo percutaneous suprapapillary biliary drainage with placement of a self-expanding metal stent across the obstruction without crossing the papilla.

    Procedure: Percutaneous suprapapillary biliary drainage with self-expanding metal stent

Interventions

  • ProcedurePercutaneous transpapillary internal-external biliary drainage

    Percutaneous biliary drainage performed by advancing a catheter across the biliary obstruction and through the papilla into the duodenum, allowing internal and external bile drainage.

    Also known as: Intervention 1

  • ProcedurePercutaneous suprapapillary biliary drainage with self-expanding metal stent

    Percutaneous biliary drainage performed by placing a self-expanding metal stent across the biliary obstruction without crossing the papilla.

    Also known as: Intervention 2

06

What researchers measure

Primary outcomes

  1. Acute cholangitis

    Defined by clinical criteria, including fever (axillary temperature \>38°C) and leukocytosis (white blood cell count \>10,000/mm³), in the absence of another infectious source on abdominal and chest imaging.

    Time frame: Within 90 days after intervention

  2. Acute cholecystitis

    Defined by radiological evidence of cholecystitis associated with fever (axillary temperature \>38°C) and leukocytosis (white blood cell count \>10,000/mm³).

    Time frame: Within 90 days after intervention

  3. Acute pancreatitis

    Defined by the presence of at least two of the following criteria: abdominal pain consistent with pancreatitis, elevation of amylase and/or lipase greater than three times the upper limit of normal, or characteristic imaging findings.

    Time frame: Within 90 days after intervention

  4. Bile leak

    Defined as intra-abdominal bile leakage due to biliary perforation or at the hepatic puncture site, confirmed by imaging.

    Time frame: Within 90 days after intervention

  5. Hemorrhage

    Defined as clinical or radiological evidence of bleeding requiring blood transfusion or reintervention.

    Time frame: Within 90 days after intervention

Secondary outcomes

  1. Therapeutic success

    Defined as a decrease in total bilirubin to \<3 mg/dL or a reduction of more than 50% compared to pre-drainage levels

    Time frame: Within 30 days after intervention

  2. Mortality

    All-cause mortality following biliary drainage.

    Time frame: Within 90 days after intervention

  3. Need for reintervention

    Requirement for additional percutaneous or endoscopic procedures

    Time frame: Within 30 days after intervention

Other outcomes

  1. Rate of curative surgery

    Number of patients from group A (patients with potentially resectable neoplasms) who undergo potentially curative surgery

    Time frame: Within 180 days of intervention

  2. 90-day postoperative mortality

    Surgical mortality in patients from Group A (patients with potentially ressectable neoplasms) who undergo potentially curative surgery

    Time frame: Within 90 days of curative surgery

  3. 90-day postoperative morbidity

    Surgical morbidity in patients from Group A (patients with potentially ressectable neoplasms) who undergo potentially curative surgery according to Clavien-Dindo classification

    Time frame: Within 90 days of curative surgery

  4. Incidence of postoperative liver failure

    Incidence of postoperative liver failure in patients from Group A (patients with potentially ressectable neoplasms) who undergo potentially resectable surgery

    Time frame: Within 90 days of curative surgery

  5. Stent patency duration

    Duration of stent patency in patients from group B (patients not candidates for potentially curative resection)

    Time frame: Within 180 days of intervention

07

Study locations

1 of 2 sites recruiting
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
    Not yet recruiting
    • Cleber R. P. Kruel, Professor · Contactcrkruel@hcpa.edu.br · +55(51)3359-8232
    • Gabriel L. da Silva, Attending Physician · Contactgablsilva@hcpa.edu.br · +55(51)3359-8232
    • Gabriel L. da Silva, Attending Physician · Sub investigator
    • Leandro A. Scaffaro, Attending Physician · Sub investigator
    • Mauricio Farenzena, Attending Physician · Sub investigator
    • Flavia H. Feier, Professor · Sub investigator
    • Pablo D. Rodrigues, Attending Physician · Sub investigator
    • Tomaz J. M. Grezzana, Attending Physician · Sub investigator
    • Marcio F. Chedid, Attending Physician · Sub investigator
    • William F. Silvano, Attending Physician · Sub investigator
    • Francisco C. B. Lemanski, General Surgery Resident · Sub investigator
    • Cleber R. P. Kruel, Professor · Principal investigator
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90610-910, Brazil
    Recruiting
08

References and documents

Publications

  • Coelen RJS, Roos E, Wiggers JK, Besselink MG, Buis CI, Busch ORC, Dejong CHC, van Delden OM, van Eijck CHJ, Fockens P, Gouma DJ, Koerkamp BG, de Haan MW, van Hooft JE, IJzermans JNM, Kater GM, Koornstra JJ, van Lienden KP, Moelker A, Damink SWMO, Poley JW, Porte RJ, de Ridder RJ, Verheij J, van Woerden V, Rauws EAJ, Dijkgraaf MGW, van Gulik TM. Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):681-690. doi: 10.1016/S2468-1253(18)30234-6. Epub 2018 Aug 17. PubMed 30122355 ↗
  • Zhao XQ, Dong JH, Jiang K, Huang XQ, Zhang WZ. Comparison of percutaneous transhepatic biliary drainage and endoscopic biliary drainage in the management of malignant biliary tract obstruction: a meta-analysis. Dig Endosc. 2015 Jan;27(1):137-45. doi: 10.1111/den.12320. Epub 2014 Sep 24. PubMed 25040581 ↗
  • Wiggers JK, Groot Koerkamp B, Cieslak KP, Doussot A, van Klaveren D, Allen PJ, Besselink MG, Busch OR, D'Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, van Gulik TM, Jarnagin WR. Postoperative Mortality after Liver Resection for Perihilar Cholangiocarcinoma: Development of a Risk Score and Importance of Biliary Drainage of the Future Liver Remnant. J Am Coll Surg. 2016 Aug;223(2):321-331.e1. doi: 10.1016/j.jamcollsurg.2016.03.035. Epub 2016 Apr 5. PubMed 27063572 ↗
  • Shim DJ, Gwon DI, Han K, Kim Y, Ko GY, Shin JH, Ko HK, Kim JH, Kim JW, Yoon HK, Sung KB. Percutaneous Metallic Stent Placement for Palliative Management of Malignant Biliary Hilar Obstruction. Korean J Radiol. 2018 Jul-Aug;19(4):597-605. doi: 10.3348/kjr.2018.19.4.597. Epub 2018 Jun 14. PubMed 29962866 ↗
  • Ribero D, Zimmitti G, Aloia TA, Shindoh J, Fabio F, Amisano M, Passot G, Ferrero A, Vauthey JN. Preoperative Cholangitis and Future Liver Remnant Volume Determine the Risk of Liver Failure in Patients Undergoing Resection for Hilar Cholangiocarcinoma. J Am Coll Surg. 2016 Jul;223(1):87-97. doi: 10.1016/j.jamcollsurg.2016.01.060. Epub 2016 Feb 13. PubMed 27049784 ↗
  • Qumseya BJ, Jamil LH, Elmunzer BJ, Riaz A, Ceppa EP, Thosani NC, Buxbaum JL, Storm AC, Sawhney MS, Pawa S, Naveed M, Lee JK, Law JK, Kwon RS, Jue TL, Fujii-Lau LL, Fishman DS, Calderwood AH, Amateau SK, Al-Haddad M, Wani S. ASGE guideline on the role of endoscopy in the management of malignant hilar obstruction. Gastrointest Endosc. 2021 Aug;94(2):222-234.e22. doi: 10.1016/j.gie.2020.12.035. Epub 2021 May 20. PubMed 34023067 ↗
  • Pietrzak J, Przybylkowski A. Endoscopic Treatment of Malignant Hilar Biliary Obstruction. Cancers (Basel). 2023 Dec 13;15(24):5819. doi: 10.3390/cancers15245819. PubMed 38136363 ↗
  • Elmunzer BJ, Smith ZL, Tarnasky P, Wang AY, Yachimski P, Banovac F, Buscaglia JM, Buxbaum J, Chak A, Chong B, Cote GA, Draganov PV, Dua K, Durkalski V, Geller BS, Jamil LH, Keswani RN, Khashab MA, Law R, Lo SK, McCarthy S, Selby JB, Singh VK, Taylor JR, Willingham FF, Spitzer RL, Foster LD; INTERCPT study group and the United States Cooperative for Outcomes Research in Endoscopy (USCORE). An Unsuccessful Randomized Trial of Percutaneous vs Endoscopic Drainage of Suspected Malignant Hilar Obstruction. Clin Gastroenterol Hepatol. 2021 Jun;19(6):1282-1284. doi: 10.1016/j.cgh.2020.05.035. Epub 2020 May 23. PubMed 32454259 ↗
  • Pavlidis ET, Pavlidis TE. Pathophysiological consequences of obstructive jaundice and perioperative management. Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):17-21. doi: 10.1016/j.hbpd.2018.01.008. Epub 2018 Jan 31. PubMed 29428098 ↗
  • Okamoto T, Fujioka S, Yanagisawa S, Yanaga K, Kakutani H, Tajiri H, Urashima M. Placement of a metallic stent across the main duodenal papilla may predispose to cholangitis. Gastrointest Endosc. 2006 May;63(6):792-6. doi: 10.1016/j.gie.2005.05.015. PubMed 16650540 ↗
  • Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, Abdalla EK, Curley SA, Capussotti L, Clary BM, Vauthey JN. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg. 2007 May;204(5):854-62; discussion 862-4. doi: 10.1016/j.jamcollsurg.2006.12.032. Epub 2007 Feb 15. PubMed 17481498 ↗
  • Luman W, Cull A, Palmer KR. Quality of life in patients stented for malignant biliary obstructions. Eur J Gastroenterol Hepatol. 1997 May;9(5):481-4. doi: 10.1097/00042737-199705000-00013. PubMed 9187881 ↗
  • Liu JG, Wu J, Wang J, Shu GM, Wang YJ, Lou C, Zhang J, Du Z. Endoscopic Biliary Drainage Versus Percutaneous Transhepatic Biliary Drainage in Patients with Resectable Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis. J Laparoendosc Adv Surg Tech A. 2018 Sep;28(9):1053-1060. doi: 10.1089/lap.2017.0744. Epub 2018 Mar 12. PubMed 29641365 ↗
  • Hameed A, Pang T, Chiou J, Pleass H, Lam V, Hollands M, Johnston E, Richardson A, Yuen L. Percutaneous vs. endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma - a systematic review and meta-analysis. HPB (Oxford). 2016 May;18(5):400-10. doi: 10.1016/j.hpb.2016.03.002. Epub 2016 Apr 4. PubMed 27154803 ↗
  • Franssen S, Rousian M, van Verschuer V, Bruno M, Doukas M, van Driel L, Homs M, Mohseny B, de Wilde R, de Jonge J, Polak W, Porte R, Bijdevaate D, Moelker A, Groot Koerkamp B. Primary percutaneous stenting for palliative biliary drainage of patients with malignant hilar biliary obstruction: TESLA trial. JHEP Rep. 2025 Sep 11;7(11):101541. doi: 10.1016/j.jhepr.2025.101541. eCollection 2025 Nov. PubMed 41113121 ↗
  • Ferrucci JT Jr, Mueller PR, Harbin WP. Percutaneous transhepatic biliary drainage: technique, results, and applications. Radiology. 1980 Apr;135(1):1-13. doi: 10.1148/radiology.135.1.7360943. PubMed 7360943 ↗
  • Farges O, Regimbeau JM, Fuks D, Le Treut YP, Cherqui D, Bachellier P, Mabrut JY, Adham M, Pruvot FR, Gigot JF. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg. 2013 Jan;100(2):274-83. doi: 10.1002/bjs.8950. Epub 2012 Nov 2. PubMed 23124720 ↗
  • Benson AB, D'Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, Chahal P, Chang DT, Cloyd J, Covey AM, Glazer ES, Goyal L, Hawkins WG, Iyer R, Jacob R, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Sahai V, Schefter T, Singh G, Stein S, Vauthey JN, Venook AP, Yopp A, McMillian NR, Hochstetler C, Darlow SD. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 May 1;19(5):541-565. doi: 10.6004/jnccn.2021.0022. PubMed 34030131 ↗
  • Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae. PubMed 15273542 ↗

Individual participant data

Plan to share: Yes — All IPD collected throughout the trial

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 2 months and ending 2 years after the publication of results

Access criteria: Access to individual participant data (IPD) and supporting documents (including the study protocol and statistical analysis plan) will be granted to researchers who provide a methodologically sound research proposal. Requests must specify the intended use of the data and will be reviewed by the study investigators in accordance with institutional policies. Data will be shared in a de-identified format to ensure participant confidentiality. Access will be provided upon reasonable request to the corresponding author, subject to approval by the investigators and applicable ethical and legal requirements. Data will be made available through secure data transfer methods.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.

Of 66 non-industry interventional studies with no phase under Cholangiocarcinoma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 28. This study's planned 30 months is below that.

Counting every sponsor, half of 67 studies reached it within 43 months; a quarter within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 30, 2026
StartActual
Jun 24, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
1 site added. Hospital de Clínicas de Porto Alegre is now Not yet recruiting
Show site
  • Hospital de Clínicas de Porto Alegre · Porto Alegre, Brazil
Oct 1, 2026
Start date
Jun 15, 2026→Jun 24, 2026 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Recruiting
    1 site added. Hospital de Clínicas de Porto Alegre is now Not yet recruiting
    Show site
    • Hospital de Clínicas de Porto Alegre · Porto Alegre, Brazil
    Start date Jun 15, 2026→Jun 24, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07558304
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Jun 24, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Cleber R. P. Kruel, Professor
Contact
crkruel@hcpa.edu.br
+55(51)3359-8232 ext. 8232
Gabriel L. da Silva, Attending Physician
Contact
gablsilva@hcpa.edu.br
+55(51)3359-8232 ext. 8232
Cleber R. P. Kruel, Professor
study chair · Hospital de Clinicas de Porto Alegre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion